Karkinos Healthcare Pvt Ltd, 21st floor, Rupa Renaissance, D33, Turbhe MIDC road, Navi Mumbai, Maharashtra, 400705, India.
Karkinos Foundation, Mumbai, Maharashtra, 400086, India.
Med Oncol. 2024 Aug 6;41(9):219. doi: 10.1007/s12032-024-02461-y.
Bladder cancer is a common malignancy worldwide, posing a substantial healthcare challenge. Current standard treatment regimens are primarily based on cisplatin, but their success is often limited by cisplatin resistance and associated toxicities. Therefore, there is an urgent need to develop effective and less toxic therapies as alternatives to cisplatin. We screened the activity of FDA-approved anti-cancer drugs on a panel of cisplatin-resistant bladder cancer cell lines. Based on initial responses, cabazitaxel was selected for further evaluation of its inhibitory effects on the phenotypic properties of these cells. Cabazitaxel, primarily used for metastatic castration-resistant prostate cancer, demonstrated remarkable efficacy in inhibiting colony formation, proliferation, and migration of cisplatin-resistant bladder cancer cells. This study highlights the potential of drug repurposing as a cost-effective and efficient strategy to overcome drug resistance in bladder cancer.
膀胱癌是一种常见的全球恶性肿瘤，对医疗保健构成了重大挑战。目前的标准治疗方案主要基于顺铂，但由于顺铂耐药性和相关毒性，其疗效往往受到限制。因此，迫切需要开发有效且毒性较小的替代顺铂的治疗方法。我们在一组顺铂耐药性膀胱癌细胞系中筛选了 FDA 批准的抗癌药物的活性。根据初步反应，选择卡巴他赛进一步评估其对这些细胞表型特性的抑制作用。卡巴他赛主要用于转移性去势抵抗性前列腺癌，对抑制顺铂耐药性膀胱癌细胞的集落形成、增殖和迁移具有显著疗效。本研究强调了药物再利用作为一种具有成本效益和高效的策略来克服膀胱癌耐药性的潜力。
